| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diphosphonates | 20 | 2025 | 63 | 7.510 |
Why?
|
| Bone Density Conservation Agents | 17 | 2025 | 55 | 6.820 |
Why?
|
| Osteoporotic Fractures | 11 | 2025 | 40 | 5.970 |
Why?
|
| Osteoporosis | 14 | 2025 | 75 | 5.970 |
Why?
|
| Bone Density | 13 | 2024 | 92 | 3.970 |
Why?
|
| Female | 125 | 2025 | 12740 | 3.280 |
Why?
|
| Femoral Fractures | 6 | 2020 | 22 | 3.080 |
Why?
|
| Humans | 135 | 2025 | 17762 | 2.920 |
Why?
|
| Aged | 76 | 2025 | 6150 | 2.910 |
Why?
|
| Breast Neoplasms | 25 | 2021 | 954 | 2.880 |
Why?
|
| Polycystic Ovary Syndrome | 6 | 2022 | 19 | 2.680 |
Why?
|
| Middle Aged | 90 | 2025 | 7988 | 2.570 |
Why?
|
| Hip Fractures | 10 | 2023 | 67 | 2.460 |
Why?
|
| California | 42 | 2025 | 2326 | 2.260 |
Why?
|
| Asian Americans | 12 | 2022 | 176 | 2.140 |
Why?
|
| Fractures, Bone | 7 | 2023 | 91 | 2.130 |
Why?
|
| Aged, 80 and over | 30 | 2025 | 1923 | 2.070 |
Why?
|
| Risk Factors | 48 | 2025 | 3356 | 2.040 |
Why?
|
| Retrospective Studies | 29 | 2024 | 2461 | 1.940 |
Why?
|
| Vitamin D | 5 | 2024 | 76 | 1.750 |
Why?
|
| Risk Assessment | 26 | 2024 | 1101 | 1.740 |
Why?
|
| Prevalence | 18 | 2024 | 886 | 1.570 |
Why?
|
| Male | 52 | 2025 | 10106 | 1.530 |
Why?
|
| Kidney Failure, Chronic | 7 | 2017 | 147 | 1.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2024 | 755 | 1.480 |
Why?
|
| Delivery of Health Care, Integrated | 8 | 2025 | 535 | 1.470 |
Why?
|
| Medication Adherence | 3 | 2019 | 245 | 1.450 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2021 | 63 | 1.440 |
Why?
|
| Cohort Studies | 35 | 2024 | 2586 | 1.410 |
Why?
|
| Pediatric Obesity | 5 | 2025 | 84 | 1.340 |
Why?
|
| Vitamin D Deficiency | 4 | 2024 | 21 | 1.280 |
Why?
|
| Body Mass Index | 18 | 2025 | 964 | 1.260 |
Why?
|
| Obesity, Morbid | 3 | 2024 | 120 | 1.250 |
Why?
|
| Diabetes Mellitus | 9 | 2024 | 487 | 1.240 |
Why?
|
| Renal Dialysis | 4 | 2017 | 54 | 1.160 |
Why?
|
| Ethnic Groups | 7 | 2017 | 485 | 1.160 |
Why?
|
| Diabetes, Gestational | 8 | 2025 | 346 | 1.150 |
Why?
|
| Adult | 50 | 2025 | 7678 | 1.140 |
Why?
|
| Jaw Diseases | 4 | 2011 | 9 | 1.120 |
Why?
|
| Osteonecrosis | 4 | 2011 | 10 | 1.110 |
Why?
|
| European Continental Ancestry Group | 9 | 2020 | 529 | 1.080 |
Why?
|
| Incidence | 17 | 2024 | 1266 | 1.030 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2019 | 246 | 1.020 |
Why?
|
| Cardiovascular Diseases | 7 | 2021 | 599 | 0.970 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 1330 | 0.960 |
Why?
|
| Electronic Health Records | 6 | 2024 | 697 | 0.940 |
Why?
|
| Patient Portals | 1 | 2024 | 24 | 0.920 |
Why?
|
| Pregnancy Complications | 3 | 2017 | 199 | 0.920 |
Why?
|
| Obesity | 12 | 2025 | 842 | 0.900 |
Why?
|
| Alendronate | 5 | 2012 | 15 | 0.880 |
Why?
|
| Overweight | 7 | 2024 | 269 | 0.880 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 1213 | 0.870 |
Why?
|
| Age Factors | 14 | 2018 | 918 | 0.870 |
Why?
|
| Premature Birth | 3 | 2015 | 137 | 0.860 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 172 | 0.840 |
Why?
|
| Aromatase Inhibitors | 3 | 2017 | 32 | 0.830 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 7 | 0.830 |
Why?
|
| Hypothyroidism | 2 | 2017 | 5 | 0.810 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 37 | 0.800 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 39 | 0.790 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 63 | 0.790 |
Why?
|
| United States | 21 | 2024 | 4003 | 0.770 |
Why?
|
| Chronic Disease | 6 | 2019 | 428 | 0.760 |
Why?
|
| Adolescent | 19 | 2024 | 3685 | 0.750 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2015 | 179 | 0.740 |
Why?
|
| Prospective Studies | 25 | 2025 | 1279 | 0.740 |
Why?
|
| Survivors | 8 | 2012 | 149 | 0.730 |
Why?
|
| Time Factors | 14 | 2020 | 1093 | 0.720 |
Why?
|
| Surveys and Questionnaires | 11 | 2024 | 1321 | 0.720 |
Why?
|
| Hyperprolactinemia | 2 | 2020 | 3 | 0.720 |
Why?
|
| Continental Population Groups | 4 | 2016 | 302 | 0.720 |
Why?
|
| Hypertension | 7 | 2017 | 504 | 0.710 |
Why?
|
| Kidney Diseases | 5 | 2011 | 53 | 0.710 |
Why?
|
| Oceanic Ancestry Group | 2 | 2019 | 33 | 0.700 |
Why?
|
| Metatarsal Bones | 1 | 2020 | 1 | 0.690 |
Why?
|
| Ankle Fractures | 1 | 2020 | 1 | 0.690 |
Why?
|
| Administration, Oral | 8 | 2020 | 85 | 0.670 |
Why?
|
| Fractures, Spontaneous | 1 | 2019 | 3 | 0.670 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2019 | 4 | 0.670 |
Why?
|
| Contraceptive Agents, Female | 1 | 2019 | 12 | 0.670 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2019 | 15 | 0.660 |
Why?
|
| Contraceptives, Oral | 1 | 2019 | 26 | 0.660 |
Why?
|
| Osteoporosis, Postmenopausal | 3 | 2012 | 42 | 0.660 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 107 | 0.640 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 34 | 0.630 |
Why?
|
| Hispanic Americans | 5 | 2017 | 404 | 0.630 |
Why?
|
| Insulin Resistance | 5 | 2014 | 134 | 0.620 |
Why?
|
| African Americans | 6 | 2017 | 472 | 0.610 |
Why?
|
| Lymphedema | 3 | 2012 | 8 | 0.580 |
Why?
|
| Thinness | 2 | 2015 | 30 | 0.570 |
Why?
|
| Nutritional Sciences | 1 | 2017 | 11 | 0.570 |
Why?
|
| Teaching | 1 | 2017 | 14 | 0.570 |
Why?
|
| Internal Medicine | 1 | 2017 | 20 | 0.570 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 153 | 0.570 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 2 | 0.570 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 18 | 0.560 |
Why?
|
| Thyroid Gland | 1 | 2017 | 4 | 0.560 |
Why?
|
| Young Adult | 16 | 2020 | 2461 | 0.560 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 6 | 0.560 |
Why?
|
| Internship and Residency | 1 | 2017 | 45 | 0.550 |
Why?
|
| Pregnancy | 13 | 2025 | 1524 | 0.530 |
Why?
|
| Child | 13 | 2025 | 2491 | 0.520 |
Why?
|
| Prehypertension | 2 | 2013 | 22 | 0.520 |
Why?
|
| Quality of Life | 7 | 2024 | 510 | 0.520 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 2 | 0.490 |
Why?
|
| Antithyroid Agents | 1 | 2015 | 3 | 0.490 |
Why?
|
| Breast Feeding | 4 | 2025 | 137 | 0.490 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 26 | 0.490 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 10 | 0.490 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 52 | 0.490 |
Why?
|
| Transition to Adult Care | 1 | 2015 | 11 | 0.480 |
Why?
|
| Treatment Outcome | 6 | 2019 | 1260 | 0.470 |
Why?
|
| Dizziness | 3 | 2019 | 3 | 0.470 |
Why?
|
| Osteosclerosis | 2 | 2012 | 2 | 0.460 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 327 | 0.460 |
Why?
|
| Postural Balance | 4 | 2019 | 10 | 0.460 |
Why?
|
| Algorithms | 2 | 2017 | 239 | 0.450 |
Why?
|
| Databases, Factual | 5 | 2019 | 315 | 0.440 |
Why?
|
| Health Behavior | 1 | 2016 | 360 | 0.430 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 415 | 0.430 |
Why?
|
| Pediatrics | 1 | 2015 | 160 | 0.430 |
Why?
|
| Parenting | 1 | 2013 | 29 | 0.420 |
Why?
|
| Cervix Uteri | 1 | 2012 | 5 | 0.410 |
Why?
|
| Uterine Cervical Diseases | 1 | 2012 | 2 | 0.410 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2012 | 1 | 0.410 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 9 | 0.400 |
Why?
|
| Postmenopause | 4 | 2017 | 242 | 0.390 |
Why?
|
| Menopause | 4 | 2015 | 68 | 0.390 |
Why?
|
| Tamoxifen | 2 | 2017 | 56 | 0.390 |
Why?
|
| Perimenopause | 1 | 2011 | 11 | 0.380 |
Why?
|
| China | 4 | 2020 | 131 | 0.380 |
Why?
|
| Mouth Diseases | 1 | 2011 | 3 | 0.380 |
Why?
|
| Oral Health | 1 | 2011 | 21 | 0.370 |
Why?
|
| HIV Infections | 3 | 2023 | 696 | 0.360 |
Why?
|
| Prognosis | 12 | 2020 | 609 | 0.350 |
Why?
|
| Lactation | 4 | 2015 | 52 | 0.350 |
Why?
|
| Health Promotion | 1 | 2013 | 281 | 0.350 |
Why?
|
| Dental Implantation, Endosseous | 1 | 2010 | 1 | 0.350 |
Why?
|
| Dental Implants | 1 | 2010 | 2 | 0.350 |
Why?
|
| Dental Restoration Failure | 1 | 2010 | 6 | 0.350 |
Why?
|
| Blood Pressure | 4 | 2017 | 302 | 0.350 |
Why?
|
| Cholesterol, LDL | 3 | 2016 | 119 | 0.340 |
Why?
|
| Retinal Diseases | 3 | 2015 | 17 | 0.320 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2025 | 167 | 0.320 |
Why?
|
| Child, Preschool | 9 | 2017 | 1419 | 0.320 |
Why?
|
| Primary Health Care | 1 | 2015 | 769 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 25 | 0.310 |
Why?
|
| Cholesterol, HDL | 2 | 2014 | 81 | 0.310 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 151 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2009 | 9 | 0.300 |
Why?
|
| Alcohol Drinking | 2 | 2012 | 373 | 0.300 |
Why?
|
| Prediabetic State | 2 | 2022 | 56 | 0.300 |
Why?
|
| Diet | 4 | 2019 | 365 | 0.290 |
Why?
|
| Gait | 3 | 2018 | 6 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2025 | 331 | 0.280 |
Why?
|
| Femur | 2 | 2020 | 10 | 0.280 |
Why?
|
| Age Distribution | 4 | 2016 | 246 | 0.280 |
Why?
|
| Secondary Prevention | 2 | 2025 | 48 | 0.270 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 26 | 0.270 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 50 | 0.260 |
Why?
|
| Sex Distribution | 3 | 2024 | 190 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 29 | 0.260 |
Why?
|
| Absorptiometry, Photon | 3 | 2016 | 50 | 0.260 |
Why?
|
| Lactic Acid | 1 | 2005 | 9 | 0.250 |
Why?
|
| Fasting | 1 | 2005 | 48 | 0.250 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 24 | 0.250 |
Why?
|
| Maternal Age | 2 | 2017 | 77 | 0.250 |
Why?
|
| Bone Resorption | 2 | 2016 | 4 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 379 | 0.240 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2013 | 90 | 0.240 |
Why?
|
| Fatigue | 2 | 2022 | 34 | 0.230 |
Why?
|
| Drug Utilization | 1 | 2025 | 128 | 0.230 |
Why?
|
| Hospitalization | 3 | 2022 | 808 | 0.230 |
Why?
|
| Patient Compliance | 1 | 2006 | 300 | 0.220 |
Why?
|
| Disease Progression | 6 | 2019 | 264 | 0.220 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 710 | 0.220 |
Why?
|
| Severity of Illness Index | 7 | 2014 | 455 | 0.220 |
Why?
|
| Infant, Newborn | 5 | 2025 | 855 | 0.220 |
Why?
|
| Retina | 2 | 2015 | 25 | 0.210 |
Why?
|
| Poverty | 1 | 2024 | 167 | 0.210 |
Why?
|
| Diabetic Nephropathies | 1 | 2023 | 26 | 0.210 |
Why?
|
| Independent Living | 1 | 2022 | 22 | 0.210 |
Why?
|
| Risk | 4 | 2017 | 517 | 0.210 |
Why?
|
| Hypertensive Retinopathy | 2 | 2012 | 3 | 0.200 |
Why?
|
| Fibroblast Growth Factors | 2 | 2013 | 11 | 0.200 |
Why?
|
| Diabetic Retinopathy | 2 | 2012 | 18 | 0.200 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 155 | 0.200 |
Why?
|
| Logistic Models | 6 | 2015 | 927 | 0.200 |
Why?
|
| Radiography | 2 | 2012 | 39 | 0.190 |
Why?
|
| Tooth Extraction | 2 | 2012 | 5 | 0.190 |
Why?
|
| Heart Failure | 2 | 2022 | 396 | 0.190 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 10 | 0.180 |
Why?
|
| Health Surveys | 2 | 2016 | 260 | 0.180 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 134 | 0.180 |
Why?
|
| Leptin | 2 | 2014 | 29 | 0.180 |
Why?
|
| Japan | 1 | 2020 | 14 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 51 | 0.180 |
Why?
|
| Philippines | 1 | 2020 | 22 | 0.180 |
Why?
|
| Pregnancy Outcome | 2 | 2012 | 156 | 0.180 |
Why?
|
| Diet Surveys | 1 | 2010 | 57 | 0.180 |
Why?
|
| Body Height | 1 | 2020 | 62 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2012 | 215 | 0.180 |
Why?
|
| Acne Vulgaris | 1 | 2020 | 8 | 0.180 |
Why?
|
| Interviews as Topic | 3 | 2012 | 305 | 0.170 |
Why?
|
| Dopamine Agonists | 1 | 2020 | 3 | 0.170 |
Why?
|
| Accidental Falls | 2 | 2017 | 38 | 0.170 |
Why?
|
| Dyslipidemias | 2 | 2014 | 62 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2016 | 108 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 20 | 0.170 |
Why?
|
| Levonorgestrel | 1 | 2019 | 5 | 0.170 |
Why?
|
| Progestins | 1 | 2019 | 25 | 0.170 |
Why?
|
| Infant | 6 | 2025 | 1192 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 382 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 98 | 0.160 |
Why?
|
| Collagen Type I | 2 | 2016 | 6 | 0.160 |
Why?
|
| Peptides | 2 | 2016 | 12 | 0.160 |
Why?
|
| Comorbidity | 3 | 2017 | 597 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2010 | 1120 | 0.160 |
Why?
|
| Sex Factors | 4 | 2017 | 644 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2010 | 264 | 0.160 |
Why?
|
| Motor Activity | 3 | 2013 | 212 | 0.150 |
Why?
|
| Lipids | 2 | 2019 | 78 | 0.150 |
Why?
|
| Mothers | 1 | 2009 | 105 | 0.150 |
Why?
|
| Mass Screening | 2 | 2014 | 677 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2009 | 166 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 56 | 0.150 |
Why?
|
| Mastectomy | 1 | 2017 | 36 | 0.150 |
Why?
|
| Family Health | 1 | 2017 | 44 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 73 | 0.150 |
Why?
|
| Teaching Materials | 1 | 2017 | 4 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 59 | 0.140 |
Why?
|
| Ibuprofen | 1 | 2007 | 9 | 0.140 |
Why?
|
| Vestibular Diseases | 1 | 2017 | 1 | 0.140 |
Why?
|
| Curriculum | 1 | 2017 | 35 | 0.140 |
Why?
|
| Mobility Limitation | 1 | 2017 | 16 | 0.140 |
Why?
|
| Body Weight | 3 | 2016 | 223 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 78 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 34 | 0.140 |
Why?
|
| Maternal Welfare | 1 | 2006 | 14 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2006 | 12 | 0.140 |
Why?
|
| Aspirin | 1 | 2007 | 63 | 0.140 |
Why?
|
| Exercise | 1 | 2011 | 492 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 65 | 0.130 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2015 | 343 | 0.130 |
Why?
|
| Reference Values | 1 | 2016 | 92 | 0.130 |
Why?
|
| Ergocalciferols | 2 | 2014 | 3 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2015 | 671 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 197 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 2017 | 325 | 0.130 |
Why?
|
| Counseling | 1 | 2017 | 189 | 0.120 |
Why?
|
| Methimazole | 1 | 2015 | 2 | 0.120 |
Why?
|
| Propylthiouracil | 1 | 2015 | 2 | 0.120 |
Why?
|
| Glucose Tolerance Test | 2 | 2012 | 108 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 271 | 0.120 |
Why?
|
| Metabolic Syndrome | 2 | 2006 | 80 | 0.120 |
Why?
|
| Postpartum Period | 2 | 2014 | 96 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 53 | 0.120 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 41 | 0.120 |
Why?
|
| Social Welfare | 1 | 2014 | 13 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2014 | 87 | 0.120 |
Why?
|
| Insulin | 2 | 2012 | 206 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 59 | 0.110 |
Why?
|
| Adiponectin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Women's Health | 2 | 2012 | 201 | 0.110 |
Why?
|
| Biomarkers | 2 | 2014 | 303 | 0.110 |
Why?
|
| Registries | 3 | 2016 | 472 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 568 | 0.110 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 6 | 0.110 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hip | 1 | 2013 | 9 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2013 | 9 | 0.110 |
Why?
|
| Physical Examination | 1 | 2013 | 20 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2015 | 164 | 0.100 |
Why?
|
| Femur Neck | 1 | 2012 | 5 | 0.100 |
Why?
|
| Health Education | 1 | 2013 | 111 | 0.100 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 1 | 0.100 |
Why?
|
| Gonadotropins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Fertility | 1 | 2012 | 8 | 0.100 |
Why?
|
| Infertility | 1 | 2012 | 4 | 0.100 |
Why?
|
| Osteolysis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Wound Healing | 1 | 2012 | 5 | 0.100 |
Why?
|
| Debridement | 1 | 2012 | 3 | 0.100 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2012 | 4 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2012 | 20 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 381 | 0.100 |
Why?
|
| Gestational Age | 1 | 2012 | 111 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 210 | 0.100 |
Why?
|
| Linear Models | 3 | 2014 | 231 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 188 | 0.100 |
Why?
|
| Hormones | 1 | 2011 | 14 | 0.100 |
Why?
|
| Communication | 1 | 2013 | 194 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 45 | 0.090 |
Why?
|
| Femoral Neck Fractures | 1 | 2011 | 1 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2011 | 11 | 0.090 |
Why?
|
| Dental Care | 1 | 2011 | 19 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 60 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 49 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2011 | 9 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2011 | 9 | 0.090 |
Why?
|
| Carotid Artery Diseases | 1 | 2011 | 12 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2016 | 183 | 0.090 |
Why?
|
| Tooth Mobility | 1 | 2010 | 1 | 0.090 |
Why?
|
| Oral Fistula | 1 | 2010 | 1 | 0.090 |
Why?
|
| Tooth Socket | 1 | 2010 | 1 | 0.090 |
Why?
|
| Radiography, Panoramic | 1 | 2010 | 2 | 0.090 |
Why?
|
| Facial Pain | 1 | 2010 | 5 | 0.090 |
Why?
|
| Life Style | 3 | 2019 | 333 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 64 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 145 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 178 | 0.090 |
Why?
|
| Osseointegration | 1 | 2010 | 3 | 0.090 |
Why?
|
| Forecasting | 1 | 2010 | 75 | 0.090 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.080 |
Why?
|
| Technetium Compounds | 1 | 2009 | 1 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 4 | 0.080 |
Why?
|
| Imidazoles | 1 | 2009 | 4 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 12 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2018 | 71 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2009 | 38 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 2 | 2015 | 46 | 0.080 |
Why?
|
| Parity | 1 | 2009 | 74 | 0.080 |
Why?
|
| Self Report | 2 | 2016 | 253 | 0.070 |
Why?
|
| Survival Rate | 3 | 2010 | 260 | 0.070 |
Why?
|
| Demography | 2 | 2013 | 101 | 0.070 |
Why?
|
| Random Allocation | 2 | 2017 | 37 | 0.070 |
Why?
|
| Abdomen | 1 | 2006 | 20 | 0.070 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2006 | 3 | 0.070 |
Why?
|
| Aromatase | 1 | 2006 | 7 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2006 | 10 | 0.070 |
Why?
|
| Calcinosis | 1 | 2006 | 40 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 154 | 0.070 |
Why?
|
| Adiposity | 1 | 2006 | 66 | 0.060 |
Why?
|
| African Continental Ancestry Group | 1 | 2006 | 162 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 630 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.060 |
Why?
|
| Neoplasms | 1 | 2009 | 444 | 0.060 |
Why?
|
| Tenofovir | 1 | 2023 | 18 | 0.060 |
Why?
|
| Albuminuria | 1 | 2023 | 38 | 0.050 |
Why?
|
| Meals | 1 | 2022 | 7 | 0.050 |
Why?
|
| Retinal Vessels | 2 | 2012 | 4 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2010 | 719 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 238 | 0.050 |
Why?
|
| Kidney | 2 | 2014 | 52 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 304 | 0.050 |
Why?
|
| Stroke | 2 | 2016 | 315 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2021 | 90 | 0.050 |
Why?
|
| Time | 1 | 2020 | 20 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 29 | 0.050 |
Why?
|
| Diet Records | 1 | 2010 | 36 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 154 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 354 | 0.040 |
Why?
|
| Energy Intake | 1 | 2010 | 101 | 0.040 |
Why?
|
| Educational Status | 1 | 2010 | 200 | 0.040 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2019 | 1 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 77 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 26 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2009 | 61 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 368 | 0.040 |
Why?
|
| Vestibule, Labyrinth | 1 | 2018 | 1 | 0.040 |
Why?
|
| New South Wales | 1 | 2018 | 2 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 27 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 44 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2018 | 46 | 0.040 |
Why?
|
| Home Care Services | 1 | 2018 | 23 | 0.040 |
Why?
|
| Social Support | 1 | 2010 | 206 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2019 | 85 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2007 | 12 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 10 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 5 | 0.040 |
Why?
|
| New Zealand | 1 | 2017 | 5 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 22 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 22 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 29 | 0.030 |
Why?
|
| Minnesota | 1 | 2017 | 53 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 6 | 0.030 |
Why?
|
| Menstruation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Colorado | 1 | 2017 | 164 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 79 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 13 | 0.030 |
Why?
|
| Research Design | 2 | 2011 | 376 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 151 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 73 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 183 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 169 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 146 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 46 | 0.030 |
Why?
|
| Venules | 1 | 2014 | 1 | 0.030 |
Why?
|
| Arterioles | 1 | 2014 | 2 | 0.030 |
Why?
|
| Retinal Artery | 1 | 2014 | 2 | 0.030 |
Why?
|
| Retinal Vein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 7 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 14 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cholecalciferol | 1 | 2014 | 15 | 0.030 |
Why?
|
| Triglycerides | 1 | 2014 | 88 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 129 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 3 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 375 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2012 | 4 | 0.030 |
Why?
|
| Photography | 1 | 2012 | 9 | 0.030 |
Why?
|
| Remission Induction | 1 | 2012 | 25 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 77 | 0.030 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2013 | 100 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2012 | 7 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 12 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 321 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 505 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.020 |
Why?
|
| Infant Food | 1 | 2011 | 8 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 8 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 137 | 0.020 |
Why?
|
| World Health Organization | 1 | 2011 | 14 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 34 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 300 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 305 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2010 | 3 | 0.020 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2010 | 6 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2011 | 228 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2011 | 417 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 51 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 39 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2006 | 14 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2006 | 88 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 53 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 181 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 22 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 190 | 0.010 |
Why?
|